Gene Expression Profiling as a Guide for the Management of Early Stage Breast Cancer

Please note: All assessments are current as of the review date; however, new evidence that may have been published subsequently is not considered.
Review Date:	October 18, 2006
Recommendation:	This topic was reviewed by the California Technology Assessment Forum on October 18, 2006. It was recommended that the use of gene expression profiling using the Oncotype DX recurrence score meets CTAF Technology Assessment Criteria 1 through 5 for safety, effectiveness and improvement in health outcomes when used with other tools to inform the decision to use chemotherapy in patients recently diagnosed with invasive breast cancer meeting the following criteria: • Tumor size less than 5 cm. • Estrogen or progesterone receptor positive • Lymph node negative It is recommended that the use of other forms of gene expression profiling, including the 70-gene prognostic signature, do not meet CTAF Technology Assessment Criteria 3 through 5 for safety, effectiveness and improvement in health outcomes.
Decision:	Partially Meets CTAF Criteria
Full Assessment:	Download (PDF)

Search Assessments